Intranasal corticosteroids for allergic rhinitis: How do different agents compare?

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 4 I, 1999, Pages

  Corren, Jonathan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intranasal steroids; Lipophilicity; Onset of action; Potency; Systemic bioavailability

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID RECEPTOR; BECLOMETASONE; BETAMETHASONE; BUDESONIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

BIOAVAILABILITY; HAY FEVER; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; PERENNIAL RHINITIS; REVIEW; ALLERGIC RHINITIS; ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; BIOLOGICAL AVAILABILITY; HUMANS; RECEPTORS, GLUCOCORTICOID; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0033495108     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70310-6     Document Type: Article

References (43)

1. Mygind N. Glucocorticosteroids and rhinitis. Allergy 1993;48:476-90.
2. International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994;49(29 Suppl):1-34.
3. McKenzie AW. Percutaneous absorption of steroids. Arch Dermatol 1962;86:611-4.
4. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998;101(Suppl):S434-9.
5. + cells. J Allergy Clin Immunol 1997;100:511-9.
6. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994;149:A212.
7. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim-Forsch/Drug Res 1998;48:956-60.
8. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
9. Nasarel (flunisolide) In: Physicians' Desk Reference. 53rd ed. Montvale (NJ): Medical Economics; 1998. p 955-6.
10. Rhinocort (budesonide). In: Physicians' Desk Reference. 53rd ed. Montvale (NJ): Medical Economics; 1999. p 591-3.
11. Flonase (fluticasone propionate) In: Physicians' Desk Reference. 53rd ed. Montvale (NJ): Medical Economics; 1999. p 591-3.
12. Nasonex (mometasone furoate) In: Physicians' Desk Reference. 53rd ed. Montvale (NJ): Medical Economics; 1999. p 2861-2.
13. Brattsand R, Axelsson BI. New inhaled glucocorticoids. In: Barnes PJ, editor. New drugs for asthma. Vol 2. London: IBC Technical Service; 1992. p 193-208.
14. Welsh PW, Stricker WE, Chu CP, Naessens JM, Reese ME, Reed CE, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987;62:125-34.
15. Ratner PH, Paull BR, Findlay SR, Hampel F Jr, Martin B, Kral KM, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily. J Allergy Clin Immunol 1992;90:285-91.
16. Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995;25:737-43.
17. van As A, Bronsky EA, Dockhorn RJ, Grossman J, Lumry W, Meltzer EO, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 1993;91:1146-54.
18. Haye R, Gomez EG. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology 1993;31:169-74.
19. Stern MA, Dahl R, Nielsen LP, Pedersen B, Schrewelius C. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997;11:323-30.
20. Day J, Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once-daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol 1998;102:902-8.
21. Andersson M, Berglund R, Greiff L, Hammarlund A, Hedbys L, Malcus I, et al. A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis. Rhinology 1995;33:1 8-21.
22. Small P, Houle PA, Day JH, Briscoe M, Gold M, Brodarec I, et al. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 1997;100:592-5.
23. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex™) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996;51:569-76.
24. Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996;98:724-31.
25. Drouin M, Yang WH, Bertrand B, Van Cauwenbergep, Clement P, Dalby K, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996;77:153-60.
26. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis: 194-079 Study Group. Ann Allergy Asthma Immunol 1997;79:237-45.
27. Juniper EF, Guyatt GH, Archer B, Ferrie PJ. Aqueous beclomethasone dipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of "as needed" use. J Allergy Clin Immunol 1993;92:66-72.
28. Nasacort (triamcinolone acetonide). In: Physicians' Desk Reference. 53rd ed. Montvale (NJ): Medical Economics; 1998. p 2956-9.
29. Vancenase AQ 84 μg (beclomethasone dipropionate, monohydrate). In: Physicians' Desk Reference. 53rd ed. Montvale (NJ): Medical Economics; 1999. p 2890-2.
30. Berkowitz RB, Nolop RB, Mesarina-Wicki BE, C93-184 Study Group. Onset of action of mometasone furoate (Nasonex) nasal spray in seasonal allergic rhinitis [abstract 1790]. J Allergy Clin Immunol 1997;99(Suppl):S441.
31. Minshall E, Ghaffar O, Cameron L, O'Brien F, Quinn H, Rowe-Jones J, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998;118:648-54.
32. Holm AF, Fokkens WJ, Godthelp T, Mulder PG, Vroom TM, Rijntjes E. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol 1998;23:69-73.
33. Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal axis activity. J Allergy Clin Immunol 1998;101:470-4.
34. Wilson AM, Sims EJ, McFarlane LC, Lipworth BJ. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998;102:598-604.
35. Wihl JA, Andersson KE, Johansson SA. Systemic effects of two nasally administered glucocorticosteroids. Allergy 1997;52:620-6.
36. Brannan MD, Herron JM, Reidenberg P, Affrine MB. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther 1995;17:637-47.
37. Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1998;102:191-7.
38. Howland WC III, Dockhorn R, Gillman S, Gross GN, Hille D, Simpson B, et al. A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis. J Allergy Clin Immunol 1996;98:32-8.
39. Nayak AS, Ellis MH, Gross GN, Mendelson LM, Schenkel EJ, Lanier BQ, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1998;101:157-62.
40. Fokkens WJ, van de Merwe JP, Braat JP, Overbeek SE, Hooijkaas H. The effect of intranasal and inhaled corticosteroids in healthy volunteers on the number of circulating lymphocytes and lymphocyte subsets. Allergy 1999;54:158-64.
41. Knutsson U, Stierna P, Marcus C, Carlstedt-Duke J, Carlström K, Broïnnegård M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol 1995;144:301-10.
42. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma: Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med 1997;337:1659-65.
43. Rachelefsky GS, Chervinsky P, Meltzer EO, Morris JM, Seltzer JM, Skoner DP, et al. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray (Vancencase AQ [VNS]) on long-term growth in children [abstract]. J Allergy Clin Immunol 1998;101(Suppl):S236.